Skip to content

IV Ketamine Vs. in Esketamine for MDD TRD

Treatment Resistant Depression

The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations.

Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 to 75

Critères de participation

Inclusion Criteria:

* Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode

Exclusion Criteria:

* Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.

Lieu de l'étude

Providence Care Hospital
Providence Care Hospital
KIngston, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Gustavo H Vazquez, MD,PhD,FRCPC

[email protected]
613-544-4900
Étude parrainée par
Queen's University
Participants recherchés
Plus d'informations
ID de l'étude: NCT06488586